Optimizing Prograf® Therapy in Renal Transplant Patients

• Status: Completed
• Trial end date: 2006-03-01
• Target enrollment: 0
• Participant gender: All

Summary

A study to determine the optimal dose and blood level of Prograf® in long-term maintenance of kidney transplant patients.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Astellas Pharma Inc
• Collaborator: Astellas Pharma US, Inc.
• Treatments: Tacrolimus

Criteria

Inclusion Criteria:

• Patient was 18 years of age at the time of transplant.

• Patient is at least 6 months post-transplant.

Exclusion Criteria:

• Patient is the recipient of a solid organ transplant other than the kidney.

• Patient is a known carrier of any of the HIV viruses.